Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
This randomized phase I trial studies the side effects and best way to give vaccine therapy
 together with basiliximab in treating patients with acute myeloid leukemia (AML) in complete
 remission. Vaccines made from the WT1 peptide may help the body build an effective immune
 response to kill cancer cells. Montanide ISA 51 VG and poly-ICLC may enhance this response.
 Monoclonal antibodies, such as basiliximab, can block cancer growth in different ways. Some
 block the ability of cancer to grow and spread. Others find cancer cells and help kill them
 or carry cancer-killing substances to them. It is not yet known whether WT1 126-134 peptide
 vaccine with Montanide ISA 51 VG is more effective than with poly-ICLC when given together
 with basiliximab in treating AML
PRIMARY OBJECTIVES:

 I. To examine the immunogenicity of WT1 peptide (WT1 126-134 peptide vaccine) emulsified in
 Montanide (Montanide ISA 51 VG) in elderly patients with AML.

 II. To determine whether toll-like receptor 3 (TLR3) agonist (poly-L-lysine and carboxymethyl
 cellulose [poly ICLC]) could be a potent immunologic adjuvant, and increases the frequencies
 of WT1-specific T cells following vaccination.

 III. To determine whether depletion of regulatory T cells occurs upon administration of the
 anti-cluster of differentiation (CD)25 monoclonal antibody Basiliximab, and whether this is
 associated with increased frequencies of WT1-specific T cells following vaccination.

 IV. To assess whether WT1 vaccination +/- TLR3 agonist (poly ICLC) combined with Basiliximab
 results in decreased levels of WT1 transcripts in peripheral blood cells compared to WT1
 vaccination +/- TLR3 as measured by quantitative reverse transcriptase-polymerase chain
 reaction (qRT-PCR).

 SECONDARY OBJECTIVES:

 I. To examine the safety and gain preliminary information on efficacy of WT1 peptide
 vaccination +/- TLR3 agonist (poly ICLC) combined with Basiliximab.

 OUTLINE: Patients are randomized to 1 of 2 treatment arms.

 ARM A: Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG
 subcutaneously (SC) on day 0 and then once every 2 weeks.

 ARM B: Patients receive WT1 126-134 peptide vaccine emulsified in poly-ICLC SC on day 0 and
 then once every 2 weeks.

 ARM C: Patients assigned to Arm C receive basiliximab intravenously (IV) over 30 minutes on
 day -7 and WT1 126-134 peptide vaccine as in Arm A or Arm B, whichever had a superior
 cellular immune response.

 In all arms, treatment continues for 12 weeks in the absence of disease progression or
 unacceptable toxicity. Patients may then receive 6 additional monthly vaccinations.

 After completion of study treatment, patients are followed up for up to 2 years.
Inclusion Criteria:

 -  Patients with Hematological malignancies, including AML, MDS, CML in blast phase and
 other conditions at the investigator's discretion.

 -  Bone marrow biopsy-confirmed CR or CRi, more than CR1 is allowed, such as CR2 or CR3.
 The enrollee is deemed not a candidate for stem cell transplant due to advanced age or
 co-morbidities; or the enrollee does not have donor available; or enrollee refuses
 stem cell transplant due to personal belief; or stem cell transplant is not current
 standard of care. Patients who are post stem cell transplant in CR or CRi are allowed
 if they are off immunosuppression,and not treated with systematic steroid for GVHD

 -  Karnofsky performance status index > or = 80%

 -  Written informed consent

 -  Absolute neutrophil count > or = 500/μl

 -  Platelet count >= 20,000/μl with transfusion

 -  Creatinine = or < 2 x upper limit of normal (ULN)

 -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate
 transaminase (SGPT) = or < 5 x ULN

 -  Bilirubin = or < 3 x ULN

 -  Human leukocyte antigens (HLA) typing: patient must express HLA-A2

 -  Age > 18 years and < 85 years

 -  Electrocardiogram (EKG) without evidence of arrhythmia or changes that indicate acute
 ischemia

 -  Pulse oximetry showing oxygen saturation of at least 90% on room air

 -  No irreversible coagulopathy, international normalized ratio (INR) =< 2

 -  No sign of tumor lysis syndrome, uric acid needs to be in normal range prior to
 treatment

 -  Not in diabetic ketoacidosis (DKA), sickle cell crisis, and not having severe
 peripheral vascular disease on active anti-coagulation treatment

 Exclusion Criteria:

 -  Pregnant or nursing women; women who still have child-bearing potential must be tested
 for urinary or serum beta human chorionic gonadotropin (βHCG)

 -  Biological or chemotherapy in the 4 weeks prior to the start of dosing

 -  Patients with intrinsic immunosuppression, including seropositivity for human
 immunodeficiency virus (HIV) antibody; patients should be tested for HIV

 -  Serious concurrent infection, including active tuberculosis, hepatitis B, or hepatitis
 C; patients should be tested for hepatitis B surface antigen and hepatitis C antibody;
 patients who are hepatitis C antibody (Ab) positive can be eligible if they are PCR
 negative

 -  Active or history of confirmed autoimmune disease

 -  Concurrent systemic corticosteroids (except physiologic replacement doses) or other
 immunosuppressive drugs (eg. cyclosporin A)

 -  Active or history of autoimmune disease including but not limited to rheumatoid
 arthritis (rheumatoid factor [RF]-positive with current or recent flare), inflammatory
 bowel disease, systemic lupus erythematosus (clinical evidence with antinuclear
 antibody [ANA] 1:80 or greater), ankylosing spondylitis, scleroderma, multiple
 sclerosis, autoimmune hemolytic anemia, and immune thrombocytopenic purpura;
 seropositivity alone will not be considered positive

 -  Psychiatric illness that may make compliance to the clinical protocol unmanageable or
 may compromise the ability of the patient to give informed consent; patients with
 clinical evidence of dementia should have a competent designee participate in decision